Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement with Sanofi for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

AstraZeneca

Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc's (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants. The data comes earlier than anticipated; regulatory submissions for all-infant indications are expected to begin in 2022.

Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants

Bayer AG

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Lockheed Martin

Merck

Philip Morris

Roche Holding AG

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The May 2021 Heat Map

Amgen

Bristol-Myers

Regeneron Pharmaceuticals

Replimune Group Inc

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Analysts See Plenty of Upside for Replimune

Sanofi's (SNY) new cancer drug, Sarclisa, gets second approval for treating multiple myeloma patients in Europe within a year.

Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate. Kazia expects to launch a phase I clinical trial of EVT801 in CY2021.

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on 11 February 2021. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum.

Sanofi completes Kiadis acquisition

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 16, paragraph 1 and 2 and Article 17 paragraph 1 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on 11 February 2021. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum.

Sanofi declares the Offer for Kiadis unconditional

Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.

Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform

Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2

U.S.-listed shares of Sanofi gained 0.7% in premarket trading on Wednesday after the company said it has formed a nonprofit business unit that will provide 30 essential medicines to 40 lower-income countries. The creation of Sanofi Global Health is part of the drug maker's corporate social responsibility plan.

Sanofi forms nonprofit unit to provide essential medicines to some low-income countries

PARIS, April 7, 2021 /PRNewswire/ -- In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. Embedded in Sanofi's long-term strategy, the company's commitment is based on four essential pillars in which Sanofi is uniquely positioned to make a difference: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees.

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

There are five billion reasons these companies hope it's not.

Is the Market For a Flu Vaccine Disappearing?

Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.

Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion

Johnson & Johnson

Vaxart

Sometimes, the huge potential gains of small biotechs are worth the risk.

These 3 Stocks Will Make You A Fortune If They Succeed

PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy. "In the Phase 3 IKEMA study, the addition of Sarclisa to carfilzomib and dexamethasone reduced risk of disease progression or death by 45%," said Thomas G.

FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Daiichi Sankyo Co Ltd

Though Daiichi Sankyo (OTCMKTS: DSNKY) and Sanofi SA (NASDAQ: SNY) came forward to help produce other pharmas' COVID-19 shots, the companies are calling it quits on their own, separate vaccine alliance in Japan.  Daiichi Sankyo has decided to suspend the Squarekids combination vaccine production and a development deal for the pentavalent combination shot VN-0105 after encountering a manufacturing snag.

Daiichi Axes Sanofi Vaccine Pact After Pertussis Jab Manufacturing Faces Snag

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - February 2021

Sanofi SA (NASDAQ: SNY) is dropping a major investment into its supply chain by shelling C$925 million to build a new manufacturing facility in Toronto. The new facility will be operational by 2026 and provide additional antigen and filling capacity for Fluzone, a high-dose flu vaccine.

Canadian Government, Sanofi To Build C$925M Flu Vaccine Facility In Toronto

AbbVie

Gilead Sciences

Eli Lilly

Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.

7 Big Pharmaceutical Stocks for Bigger Income

Adicet Bio, Inc.

Editas Medicine

Immatics NV

Sesen Bio Inc.

Shattuck Labs

LAVA Therapeutics has filed to raise $101 million in an IPO.

LAVA Therapeutics Seeks $101 Million U.S. IPO

Global Blood Therapeutics

Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY). One program pursues a novel anti-sickling mechanism, and the other leverages a new approach to reduce inflammation and oxidative stress.

GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi

Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.

Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer

Telesis Bio Inc

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

News for Sanofi Stock (SNY)